ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

1:00PM-2:30PM: Abstract Number: 0805

Results from the Certolizumab-pegol Pregnancy Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project

Abstracts: Reproductive Issues in Rheumatic Disorders

1:00PM-2:30PM: Abstract Number: 0777

Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease I

1:00PM-2:30PM: Abstract Number: 0806

Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events

Abstracts: Reproductive Issues in Rheumatic Disorders

1:00PM-2:30PM: Abstract Number: 0784

RUNX1 Is Expressed in a Subpopulation of Dermal Fibroblasts and Is Increased with Systemic Sclerosis Disease Severity

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

1:00PM-2:30PM: Abstract Number: 0793

Secular Changes in Widespread Pain Across Two Generations: The Framingham Heart Study

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia

1:00PM-2:30PM: Abstract Number: 0804

Serologic and Clinical Predictors of Progressive Pulmonary Fibrosis in Rheumatoid Arthritis-associated Interstitial Lung Disease Progression: A Prospective Longitudinal Cohort

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Breathe: RA-ILD

1:00PM-2:30PM: Abstract Number: 0803

Serum Adipokines and Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Breathe: RA-ILD

1:00PM-2:30PM: Abstract Number: 0779

Sex Differences in the B Cell Compartment of Patients with Oligoarticular Juvenile Idiopathic Arthritis

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease I

1:00PM-2:30PM: Abstract Number: 0794

Social Security Work Disability and Its Predictors in Patients with Fibromyalgia: 25 Years of Followup

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia

1:00PM-2:30PM: Abstract Number: 0783

Spatial Reconstruction of Interstitial Lung Disease

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

1:00PM-2:30PM: Abstract Number: 0819

The Assessment of SpondyloArthritis International Society (ASAS) Definition of Difficult-to-Manage Axial Spondyloarthritis

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes I

1:00PM-2:30PM: Abstract Number: 0820

The Classification in Axial Spondyloarthritis Inception Cohort Study: Performance of the 2009 Assessments in Spondyloarthritis International Society Classification Criteria

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes I

1:00PM-2:30PM: Abstract Number: 0824

The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with ENT Manifestations of ANCA-Associated Vasculitis (AAV): Post Hoc Analysis of Subset of Patients Recruited to the PROTECT-V Trial

Abstracts: Vasculitis – ANCA-Associated I

1:00PM-2:30PM: Abstract Number: 0809

The Utility of the sFlt1:PlGF Ratio to Rule out and Predict Preeclampsia in Women with Lupus

Abstracts: Reproductive Issues in Rheumatic Disorders

1:00PM-2:30PM: Abstract Number: 0821

Validation of ASAS Preliminary Data-Driven MRI Lesion Cut-offs for a Positive MRI of the Sacroiliac Joints in Patients with Axial Spondyloarthritis and Subgroups with Psoriasis, Iritis, and Colitis

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].